http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2595809-C2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7241b09d23ed4f6338194f8c466304ba |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate | 2013-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2016-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf82fefd4b7bc03131dd38c3f32f3a8a |
publicationDate | 2016-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2595809-C2 |
titleOfInvention | Therapeutic agent |
abstract | FIELD: medicine. n SUBSTANCE: present group of inventions concerns treating multiple sclerosis in experiment. That is a therapeutic agent representing an activated potentiated antibodies to brain-specific protein S-100. n EFFECT: injection drug experimental animals removed time of occurrence of signs of autoimmune encephalomyelitis and reduced severity of clinical manifestations of the disease. n 9 cl, 4 dwg, 2 ex |
priorityDate | 2013-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 658.